|
Background: Uterine fibroids are the most common pelvic tumors and most common benign tumors in women. Abnormal uterine bleeding and pain are common symptoms of fibroids. The objective of study was to study the effect of mifepristone on uterine fibroids on the basis of change in menstrual pattern, hemoglobin level, fibroid volume and alleviation of pain. Methods: This prospective study had sample size of 40 subjects with uterine leiomyomas who were recruited from OPD after taking an informed written consent. Follow up of each subject was done after 3 months to see changes in various parameters after giving 3 months of mifepristone 25 mg once daily. Study tools included case reporting form, ultrasonography, blood investigations, pictorial blood loss assessment chart (PBAC) to compare change in menstrual pattern and visual analogue pain scale for comparing alleviation in pain. Results: In this study, the majority of patients belonged to 41-45 years of age and were para 1 with dominant symptom of menorrhagia. At the end of 3 months the mean baseline fibroid volume decreased by 37.5%, mean hemoglobin improved from 9.37 to 11.05 gm/dl, mean PBAC score reduced from 90.6 to 8.9, 25% of patients had no pain and pain score in 32.5% patients was 1 and in 32.5% patients pain score was 2. Conclusions: Three months treatment with 25 mg mifepristone daily, effectively controls bleeding, reduces fibroid volume ameliorates pain and abnormal bleeding, improves hemoglobin. It can be recommended as the optimum clinical treatment of fibroids in this dose.
|
